Compare American Express Co (AXP) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Express Co vs TG Therapeutics Inc — how do they compare? American Express Co trades at $361.45 (market cap $242.27B), while TG Therapeutics Inc trades at $55.95 (market cap $8.41B). The key difference: American Express Co is far larger — about 28.8× TG Therapeutics Inc's market cap, and American Express Co pays a 1.07% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AXP | TGTX | |
|---|---|---|
Market Cap | $242.27B | $8.41B |
Sector | Financials | Health |
52-Week High | $384.82 | $59.06 |
52-Week Low | $292.27 | $26.39 |
Dividend Yield | 1.07% | — |
Enterprise Value | — | $8.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXP trades at $354.43, up 1.1% today, with a bullish technical signal from moving averages and support at $352. The company reported strong Q1 2026 earnings of $4.28 per share, beating estimates, with revenue reaching $72.23 billion in 2025. Recent news highlights AI investments and a new headquarters, while analyst consensus is a $373.62 price target with 40% buy ratings.
Outlook remains positive driven by revenue growth and premium cardholder expansion, but risks include economic sensitivity and rising debt levels. The stock offers potential upside to consensus targets, supported by institutional confidence and operational momentum, though investors should monitor spending trends and interest rate impacts.
TG Therapeutics (TGTX) trades at $55.01, down 3.69% today, with a bullish technical signal from moving averages and a consensus analyst rating of 'Buy' from 11 of 13 analysts. The company reported strong revenue growth to $616.29 million in 2025 and a net income of $447.18 million, though recent quarterly EPS misses and negative operating cash flow of -$24.77 million highlight volatility. Positive news includes Phase II trials for Briumvi in schizophrenia and Phase I success in myasthenia gravis, driving investor optimism.
Outlook: TGTX offers growth potential through pipeline expansion and robust sales guidance, but faces risks from clinical trial outcomes, cash flow challenges, and high valuation multiples. The stock's 70% year-to-date gain reflects high expectations, requiring careful monitoring of execution against earnings forecasts and regulatory milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Express Co
American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.
Read more on AXP →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
